Painreform 

Yahoo Finance • 22 days ago

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy

TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio’s patented, drop-less, intraoperat... Full story

Yahoo Finance • 2 months ago

PainReform’s DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects

PainReform Ltd TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured... Full story

Yahoo Finance • 3 months ago

PainReform Provides Business Update for the Six Months Ended June 30, 2025

TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologi... Full story

Yahoo Finance • 4 months ago

Form 6K Painreform Ltd For: 19 August

... Full story

Yahoo Finance • 4 months ago

PainReform/DeepSolar Accepted into NVIDIA Connect Program

TEL AVIV, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, PainReform’s solar energy business unit developing next-generation AI-driven solar analytics, has been accepted into the... Full story

Yahoo Finance • 4 months ago

PainReform acquires majority stake in LayerBio to advance eye surgery drug

TEL AVIV - PainReform Ltd. (NASDAQ:PRFX), a micro-cap biotech company with a market capitalization of $2.7 million and currently trading at $1.35 per share, has completed its previously announced investment in LayerBio, Inc., acquiring a m... Full story

Yahoo Finance • 4 months ago

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the closing of its previously announced investment in LayerBio, Inc., a privately held Boston-based... Full story

Yahoo Finance • 8 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization Market

TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion i... Full story

Yahoo Finance • 9 months ago

PainReform Provides Year-End Business Update

TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of the... Full story

Yahoo Finance • 10 months ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announ... Full story

Yahoo Finance • 2 years ago

PainReform Provides Business Update for the Third Quarter of 2023

TEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provide... Full story

Yahoo Finance • 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announ... Full story

Yahoo Finance • 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announ... Full story

Yahoo Finance • 2 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announc... Full story

Yahoo Finance • 2 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

TEL AVIV, Israel, July 12, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announc... Full story

Yahoo Finance • 3 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announc... Full story

Yahoo Finance • 3 years ago

PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, May 18, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announce... Full story

Yahoo Finance • 3 years ago

PainReform Provides Business Update for the First Quarter of 2023

TEL AVIV, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided... Full story

Yahoo Finance • 3 years ago

PainReform CEO to Present at Aegis Virtual Conference on May 4th

TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announce... Full story

Yahoo Finance • 3 years ago

PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th

TEL AVIV, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announ... Full story